Amgen AMGN today
announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA
(Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial
following the recommendation of an independent Data Monitoring Committee (DMC)
overseeing the trial. Based on the review of a pre-planned interim analysis,
the DMC concluded that the addition of ganitumab to gemcitabine is unlikely to
demonstrate a statistically significant improvement in the primary endpoint of
overall survival compared to gemcitabine alone. There were no safety concerns
raised in the DMC review of the study.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in